Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | BACE1 | P56817 | 4/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816684 | 0.91 | ACHE (0.47) | ACHEBACE1BCHESIGMAR1GAA | |
| SCHEMBL2812972 | 0.89 | SIGMAR1 (0.38) | ACHEBACE1SIGMAR1MEN1KMT2A | |
| SCHEMBL2811945 | 0.87 | ACHE (0.38) | ACHEBACE1BCHEMEN1KMT2A | |
| SCHEMBL2812214 | 0.87 | ADORA2A (0.42) | SIGMAR1GAAAPP | |
| SCHEMBL537584 | 0.86 | ACHE (0.45) | ACHEBACE1SIGMAR1APPMEN1 | |
| SCHEMBL2813853 | 0.84 | BACE1 (0.42) | ACHEBACE1BCHESIGMAR1MEN1 | |
| SCHEMBL2813048 | 0.83 | IP6K1 (0.40) | SIGMAR1MEN1KMT2A | |
| SCHEMBL2814513 | 0.83 | CXCR4 (0.37) | ACHEBACE1MEN1KMT2A | |
| SCHEMBL2812302 | 0.82 | ACHE (0.37) | ACHEBACE1MEN1KMT2A | |
| SCHEMBL2813035 | 0.82 | MCHR1 (0.36) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | ACHE 4402/4885BACE1 3588/4885BCHE 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.